A phase 2 trial of sibeprenlimab in patients with IgA nephropathy
Background A proliferation-inducing ligand (APRIL) is implicated in the pathogenesis of IgA
nephropathy. Sibeprenlimab is a humanized IgG2 monoclonal antibody that binds to and …
nephropathy. Sibeprenlimab is a humanized IgG2 monoclonal antibody that binds to and …
Long-term outcomes in IgA nephropathy
D Pitcher, F Braddon, B Hendry, A Mercer… - Clinical Journal of the …, 2023 - journals.lww.com
Background IgA nephropathy can progress to kidney failure, and risk assessment soon after
diagnosis has advantages both for clinical management and the development of new …
diagnosis has advantages both for clinical management and the development of new …
IgA nephropathy: Current understanding and perspectives on pathogenesis and targeted treatment
Y Du, T Cheng, C Liu, T Zhu, C Guo, S Li, X Rao, J Li - Diagnostics, 2023 - mdpi.com
Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis
worldwide, with varied clinical and histopathological features between individuals …
worldwide, with varied clinical and histopathological features between individuals …
[HTML][HTML] Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of …
J Barratt, R Lafayette, J Kristensen, A Stone… - Kidney international, 2023 - Elsevier
The therapeutic potential of a novel, targeted-release formulation of oral budesonide
(Nefecon) for the treatment of IgA nephropathy (IgAN) was first demonstrated by the phase …
(Nefecon) for the treatment of IgA nephropathy (IgAN) was first demonstrated by the phase …
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
R Lafayette, J Kristensen, A Stone, J Floege, V Tesař… - The Lancet, 2023 - thelancet.com
Background IgA nephropathy is a chronic immune-mediated kidney disease and a major
cause of kidney failure worldwide. The gut mucosal immune system is implicated in its …
cause of kidney failure worldwide. The gut mucosal immune system is implicated in its …
Effectiveness of mycophenolate mofetil among patients with progressive IgA nephropathy: a randomized clinical trial
Importance The role of mycophenolate mofetil (MMF) in management of immunoglobulin A
nephropathy (IgAN) remains highly controversial. Objective To evaluate the efficacy and …
nephropathy (IgAN) remains highly controversial. Objective To evaluate the efficacy and …
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
Background Sparsentan, a novel, non-immunosuppressive, single-molecule, dual
endothelin angiotensin receptor antagonist, significantly reduced proteinuria versus …
endothelin angiotensin receptor antagonist, significantly reduced proteinuria versus …
[HTML][HTML] Targeting the alternative complement pathway with iptacopan to treat IgA nephropathy: design and rationale of the APPLAUSE-IgAN study
DV Rizk, BH Rovin, H Zhang, N Kashihara… - Kidney international …, 2023 - Elsevier
Introduction Targeting the alternative complement pathway (AP) is an attractive therapeutic
strategy because of its role in immunoglobulin A nephropathy (IgAN) pathophysiology …
strategy because of its role in immunoglobulin A nephropathy (IgAN) pathophysiology …
Effects of modified Huangqi Chifeng decoction on the IL-17 signaling pathway in an IgA nephropathy rat model
S Ma, B Yang, M Zhao, P Li, J Fan, M Chang… - Journal of …, 2023 - Elsevier
Ethnopharmacological relevance Immunoglobulin A nephropathy (IgAN) is an immune-
related primary glomerular disease prevalent worldwide, with complicated clinical …
related primary glomerular disease prevalent worldwide, with complicated clinical …